Filtered By:
Management: Partnerships
This page shows you your search results in order of relevance. This is page number 6.
Order by Relevance | Date
Total 212 results found since Jan 2013.
NIH inks $5m partnership with PathMaker Neurosystems for MyoRegulator spasticity device
PathMaker Neurosystems said today it signed a $5 million cooperative partnership deal with the National Institutes of Health to support continued development of its MyoRegulator neurostimulation system designed to treat spasticity secondary to stroke.
The MyoRegulator device, based on PathMaker’s DoubleStim technology, is designed to provide simultaneous, non-invasive stimulation at spinal and peripheral locations, the Boston and Paris-based company said.
The money comes as part of a four-year grant awarded through the CREATE Devices program which also provides a partnership with the NIH’s National Institute of ...
Source: Mass Device - February 7, 2018 Category: Medical Devices Authors: Fink Densford Tags: Business/Financial News Neuromodulation/Neurostimulation PathMaker Neurosystems Inc. Source Type: news
Millennials Struggling to Care for Aging Baby Boomer Parents Call for Better Paid Leave
When Oniqa Moonsammy, 33, brought her uncle home from the hospital in early February following his stroke late last year, she planned to help her mother care for the 62-year-old as he regained his strength, figured out how to brush his own teeth again and managed his medications. But when they opened the door to the Brooklyn, N.Y., home her uncle shared with his father, Moonsammy saw her grandfather slumped in a chair. He, too, was having a severe stroke.
Moonsammy used to work five days a week as a hostess at a restaurant in Brooklyn and often spent time with her boyfriend or went to bars with friends. Now her life revolv...
Source: TIME: Health - March 19, 2018 Category: Consumer Health News Authors: Abigail Abrams Tags: Uncategorized Aging caregivers caregiving family leave FMLA paid family leave Source Type: news
Brainomix Secures £7m ($9.8m) Investment to Tackle Strokes With AI
Brainomix builds on partnership with Boehringer Ingelheim for AI-assisted fast treatment of stroke victims in latest venture round.
OXFORD, England, April 3, 2018 -- (Healthcare Sales & Marketing Network) -- Brainomix, a medical imaging company using a... Devices, Neurology, Venture Capital Brainomix, Boehringer Ingelheim, stroke, e-ASPECTS
Source: HSMN NewsFeed - April 3, 2018 Category: Pharmaceuticals Source Type: news
Shared decision-making in atrial fibrillation: navigating complex issues in partnership with the patient
AbstractAtrial fibrillation (AF) is an important risk factor for stroke. Although anticoagulation is effective in mitigating this risk, many high-risk patients are not anticoagulated in routine practice. Furthermore, as many as 50% of those who are prescribed an anticoagulant stop treatment within a year. This under treatment may be due, in part, to difficulty in navigating difficult decisions about initiating potentially lifelong therapy with significant costs, potential risks, and impact on daily life. To address these challenges, the most recent American guidelines issued a class I recommendation to use shared decision-...
Source: Journal of Interventional Cardiac Electrophysiology - October 17, 2018 Category: Cardiology Source Type: research
From Hospital to Home to Participation: A Position Paper on Transition Planning Poststroke
Based on a review of the evidence, members of the American Congress of Rehabilitation Medicine Stroke Group ’s Movement Interventions Task Force offer these 5 recommendations to help improve transitions of care for patients and their caregivers: (1) improving communication processes; (2) using transition specialists; (3) implementing a patient-centered discharge checklist; (4) using standardized outcome measures; and (5) establishing partnerships with community wellness programs.Because of changes in health care policy, there are incentives to improve transitions during stroke rehabilitation.
Source: Archives of Physical Medicine and Rehabilitation - November 19, 2018 Category: Rehabilitation Authors: Kristine K. Miller, Susan H. Lin, Marsha Neville Tags: Special communication Source Type: research
Health Worker Training Is Improving Hypertension Care and Prevention in Senegal
October 31, 2019During interviews with almost 2,000 health workers and clients in Dakar, Senegal, IntraHealth International found that some 40% of health workers had not been trained to care for clients with hypertension, and 83% of clients who did not have hypertension knew no more than a single warning sign. But a 2019 evaluation reveals significant progress in under two years.The results from our 2017-2018 situational analysis uncovered gaps in hypertension care and prevention in Dakar, including insufficiencies in equipment, hypertension management skills, and patient education.Those results helped guide theBetter Hear...
Source: IntraHealth International - October 31, 2019 Category: International Medicine & Public Health Authors: mnathe Tags: Senegal Neema Noncommunicable Diseases Human Resources Management Primary Health Care Source Type: news
Feasibility of unattended home sleep apnea testing in a cognitively impaired clinic population
Journal of Clinical Sleep Medicine, Ahead of Print.
Source: Journal of Clinical Sleep Medicine : JCSM - October 23, 2020 Category: Sleep Medicine Authors: David R. ColelliSandra E. BlackMario MasellisBenjamin LamAndrew S.P. LimMark I. Boulos1L.C. Campbell Cognitive Neurology Research Unit, Sunnybrook Health Sciences Centre, Heart and Stroke Foundation Canadian Partnership for Stroke Recovery, Hurvitz Brain Source Type: research
Janssen ’s Save Legs. Change Lives.™ is Creating a More Equitable Future for Communities at Risk of PAD-Related Amputations
TITUSVILLE, NJ, November 4, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the first impact summary for its Save Legs. Change Lives.™ Spot Peripheral Artery Disease Now multi-year initiative, designed to create urgency and action around the hidden threat of peripheral artery disease (PAD)-related amputation. In its inaugural year, Save Legs. Change Lives.™ focused on reaching Black Americans, who are up to four times more likely than white Americans to have a PAD-related amputation.1 With this critical initiative, Janssen is focused on helping those at risk of PAD through more th...
Source: Johnson and Johnson - November 4, 2022 Category: Pharmaceuticals Tags: Latest News Source Type: news
Roche and Alnylam report positive topline results from Phase 2 study KARDIA-1 of zilebesiran, an investigational RNAi therapeutic in development to treat hypertension in patients at high risk of cardiovascular disease
Zilebesiran met primary endpoint demonstrating greater than 15 mmHg reduction of systolic blood pressure at three months of treatment compared to placeboStudy met key secondary endpoints showing consistent and sustained reductions of systolic blood pressure at six monthsZilebesiran demonstrated an encouraging safety and tolerability profile in adult patients with mild-to-moderate hypertensionFull study results to be presented at an upcoming scientific conferenceBasel, 7 September 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) and Alnylam announced today that the Phase 2 study KARDIA-1 of zilebesiran, an investigational RNAi the...
Source: Roche Media News - September 7, 2023 Category: Pharmaceuticals Source Type: news
£120 million investment for research to improve NHS services
Each research project will involve collaborative partnerships between a university and surrounding NHS organisations and will be overseen by the National Institute of Health Research (NIHR).
The Collaborations for Leadership in Applied Health Research and Care (CLAHRCs) were first trialled in 2008, aimed at turning high quality research of patient needs into uppermost levels of care in the NHS. Previous CLAHRCs have undertaken research into areas such as blood-clotting drugs, telephone counselling and tools to assess the needs of stroke sufferers.
Source: NHS Networks - January 10, 2013 Category: UK Health Authors: Maria Axford Source Type: news
Partnerships Can Fight Childhood Obesity in Tennessee (Opinion)
America has a weight problem — and I’m not simply referring to the few extra pounds many of us pick up over the holidays. According to the Centers for Disease Control and Prevention, nearly 70 percent of Americans are either overweight or obese, and our wide waistlines put us at greater risk for life-threatening health conditions such as heart disease, stroke, type 2 diabetes and several types of cancer. Unfortunately, Tennesseans fare worse than most.
Source: RWJF News Digest - Childhood Obesity - January 25, 2013 Category: Eating Disorders and Weight Management Source Type: news
The Sur1-Trpm4 Channel Molecular Bases of Disease
The sulfonylurea receptor 1 (Sur1)-NCCa-ATP channel plays a central role in necrotic cell death in central nervous system (CNS) injury, including ischemic stroke, and traumatic brain and spinal cord injury. Here, we show that Sur1-NCCa-ATP channels are formed by co-assembly of Sur1 and transient receptor potential melastatin 4 (Trpm4). Co-expression of Sur1 and Trpm4 yielded Sur1-Trpm4 heteromers, as shown in experiments with Förster resonance energy transfer (FRET) and co-immunoprecipitation. Co-expression of Sur1 and Trpm4 also yielded functional Sur1-Trpm4 channels with biophysical properties of Trpm4 and pharmacologic...
Source: Journal of Biological Chemistry - February 1, 2013 Category: Chemistry Authors: Woo, S. K., Kwon, M. S., Ivanov, A., Gerzanich, V., Simard, J. M. Tags: Membrane Biology Source Type: research
Novel Oral Anticoagulants and Gastrointestinal Bleeding: a Case for Cardiogastroenterology
With the rapidly evolving cardiology drug pipeline for treatment of acute coronary syndrome (ACS), gastroenterologists have witnessed the emergence of a new population of patients who are vulnerable to gastrointestinal (GI) bleeding: the chronic cardiac patient. ACS, causing myocardial infarction (MI) and unstable angina, and atrial fibrillation are the signature conditions of the chronic cardiac patient. The morbidity and mortality of ACS is significant. Chronic cardiac patients are prescribed complex antithrombotic therapy (CAT) (ie, aspirin [ASA] plus a thienopyridine, eg, clopidogrel [Plavix; Bristol-Myers Squibb/Sanof...
Source: Clinical Gastroenterology and Hepatology - January 23, 2013 Category: Gastroenterology Authors: Neena S. Abraham Tags: Comment From the Editor Source Type: research
